Vanguard Group’s Surface Oncology, Inc. Common Stock SURF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,309,286
| Closed | -$2.01M | – | 4583 |
|
|
2023
Q2 | $2.01M | Hold |
2,309,286
| – | – | ﹤0.01% | 3659 |
|
|
2023
Q1 | $1.61M | Hold |
2,309,286
| – | – | ﹤0.01% | 3750 |
|
|
2022
Q4 | $1.89M | Buy |
2,309,286
+816
| +0% | +$804 | ﹤0.01% | 3678 |
|
|
2022
Q3 | $2.4M | Buy |
2,308,470
+508,090
| +28% | +$812K | ﹤0.01% | 3677 |
|
|
2022
Q2 | $2.95M | Buy |
1,800,380
+279,377
| +18% | +$580K | ﹤0.01% | 3634 |
|
|
2022
Q1 | $4.47M | Buy |
1,521,003
+61,098
| +4% | +$214K | ﹤0.01% | 3586 |
|
|
2021
Q4 | $6.98M | Buy |
1,459,905
+250,684
| +21% | +$1.62M | ﹤0.01% | 3430 |
|
|
2021
Q3 | $9.15M | Buy |
1,209,221
+13,789
| +1% | +$88.2K | ﹤0.01% | 3290 |
|
|
2021
Q2 | $8.92M | Buy |
1,195,432
+113,010
| +10% | +$871K | ﹤0.01% | 3267 |
|
|
2021
Q1 | $8.44M | Buy |
1,082,422
+71,920
| +7% | +$719K | ﹤0.01% | 3243 |
|
|
2020
Q4 | $9.34M | Buy |
1,010,502
+132,626
| +15% | +$1.15M | ﹤0.01% | 3030 |
|
|
2020
Q3 | $6.06M | Buy |
877,876
+404,699
| +86% | +$2.46M | ﹤0.01% | 3048 |
|
|
2020
Q2 | $3.1M | Hold |
473,177
| – | – | ﹤0.01% | 3301 |
|
|
2020
Q1 | $885K | Sell |
473,177
-500
| -0.1% | -$1.32K | ﹤0.01% | 3524 |
|
|
2019
Q4 | $891K | Sell |
473,677
-1,036
| -0.2% | -$1.73K | ﹤0.01% | 3670 |
|
|
2019
Q3 | $674K | Sell |
474,713
-114,660
| -19% | -$250K | ﹤0.01% | 3749 |
|
|
2019
Q2 | $1.66M | Sell |
589,373
-31,573
| -5% | -$126K | ﹤0.01% | 3522 |
|
|
2019
Q1 | $2.96M | Buy |
620,946
+432,139
| +229% | +$2.13M | ﹤0.01% | 3331 |
|
|
2018
Q4 | $801K | Sell |
188,807
-250,270
| -57% | -$1.93M | ﹤0.01% | 3627 |
|
|
2018
Q3 | $4.8M | Buy |
439,077
+135,216
| +44% | +$1.58M | ﹤0.01% | 3255 |
|
|
2018
Q2 | $4.96M | Buy |
+303,861
| New | +$4.4M | ﹤0.01% | 3219 |
|
Vanguard Group's SURF Position: Q3 2023 in Review
Vanguard Group sold out of Surface Oncology, Inc. Common Stock (SURF) in Q3 2023, closing a stake of 2,309,286 shares — an estimated $2.01M sold.
Vanguard Group first reported a position in SURF in Q2 2018 and held it in 21 quarters. The position peaked at $9.34M in Q4 2020. 0 funds tracked by Wall St. Rank hold SURF as of Q3 2023.
- Vanguard Group reported no remaining Surface Oncology, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Vanguard Group sold 2,309,286 Surface Oncology, Inc. Common Stock shares in Q3 2023, an estimated $2.01M.
- Vanguard Group first reported a position in Surface Oncology, Inc. Common Stock in Q2 2018 and held it in 21 quarters.
- Vanguard Group's Surface Oncology, Inc. Common Stock position peaked at $9.34M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q3 2023.
Based on Vanguard Group's 13F filing for Q3 2023, filed 14 Nov 2023.